Mesoblast hits recruitment milestone in pivotal Phase 3 chronic back pain trial
Mesoblast (NASDAQ:MESO) announced a significant clinical milestone on Wednesday, April 29, 2026, confirming that its pivotal Phase 3 trial (MSB-DR004) for rexlemestrocel-L has successfully met its patient recruitment target.





_1389300_640x360_2498168387762-640x360.webp&w=3840&q=75)
_1389307_640x360_2498171459537-640x360.webp&w=3840&q=75)


_1389238_640x360_2498163779755-640x360.webp&w=3840&q=75)
_1389236_640x360_2498164803590-640x360.webp&w=3840&q=75)
